Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

類似資料

• Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
  著者:: Allouchery, Violette, 等
  出版事項: (2018)
• Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
  著者:: Clatot, Florian, 等
  出版事項: (2016)
• Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy
  著者:: Lambertini, Matteo, 等
  出版事項: (2019)
• Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma
  著者:: Fontanilles, Maxime, 等
  出版事項: (2020)
• Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
  著者:: Fontanilles, Maxime, 等
  出版事項: (2020)